Lijie Rong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lijie Rong has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Xiao Li
Key Laboratory of Protein and Peptide Pharmaceuticals, Chinese Academy of Sciences-University of Tokyo, Beijing, 100101, China
2 shared publicationsXiaoman Liu
Key Laboratory of Protein and Peptide Pharmaceuticals, Chinese Academy of Sciences-University of Tokyo, Beijing, 100101, China
2 shared publications- Zhihai Qin
Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
2 shared publications Andrew Kossenkov
Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, USA
1 shared publicationAnna M. Puzio-Kuter
Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
1 shared publication- Bo Zhao
Key Laboratory of Genetic Evolution & Animal Models, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 6 September 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
ARID1A promotes genomic stability through protecting telomere cohesion
ARID1A inactivation causes mitotic defects. Paradoxically, cancers with high ARID1A mutation rates typically lack copy number alterations (CNAs). Here, we show that ARID1A inactivation causes defects in telomere cohesion, which selectively eliminates gross chromosome aberrations during mitosis. ARID1A promotes the expression of cohesin subunit STAG1 that is specifically required for telomere cohesion. ARID1A inactivation causes telomere damage that can be rescued by STAG1 expression. Colony formation capability of single cells in G2/M, but not G1 phase, is significantly reduced by ARID1A inactivation. This correlates with an increase in apoptosis and a reduction in tumor growth. Compared with ARID1A wild-type tumors, ARID1A-mutated tumors display significantly less CNAs across multiple cancer types. Together, these results show that ARID1A inactivation is selective against gross chromosome aberrations through causing defects in telomere cohesion, which reconciles the long-standing paradox between the role of ARID1A in maintaining mitotic integrity and the lack of genomic instability in ARID1A-mutated cancers.
- 6 September 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Open AccessARID1A promotes genomic stability through protecting telomere cohesion
ARID1A inactivation causes mitotic defects. Paradoxically, cancers with high ARID1A mutation rates typically lack copy number alterations (CNAs). Here, we show that ARID1A inactivation causes defects in telomere cohesion, which selectively eliminates gross chromosome aberrations during mitosis. ARID1A promotes the expression of cohesin subunit STAG1 that is specifically required for telomere cohesion. ARID1A inactivation causes telomere damage that can be rescued by STAG1 expression. Colony formation capability of single cells in G2/M, but not G1 phase, is significantly reduced by ARID1A inactivation. This correlates with an increase in apoptosis and a reduction in tumor growth. Compared with ARID1A wild-type tumors, ARID1A-mutated tumors display significantly less CNAs across multiple cancer types. Together, these results show that ARID1A inactivation is selective against gross chromosome aberrations through causing defects in telomere cohesion, which reconciles the long-standing paradox between the role of ARID1A in maintaining mitotic integrity and the lack of genomic instability in ARID1A-mutated cancers.
- Open Access
- 16 October 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (57) , 97231-97245
Identifying tumor promoting genomic alterations in tumor-associated fibroblasts via retrovirus-insertional mutagenesis
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Lijie Rong1, 2, 3, *, Yangyang Bian1, *, Shubai Liu2, 3, *, Xiaoman Liu2, 3, Xiao Li2, 3, **, Haiyang Liu2, 3, 4, Jinxue Zhou5, Jirun Peng6, 7, 8, Henghui Zhang9, Hongsong Chen9 and Zhihai Qin1, 2, 3 1Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, China 2Key Laboratory of Protein and Peptide Pharmaceuticals, Chinese Academy of Sciences-University of Tokyo, Beijing, 100101, China 3Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China 4University of Chinese Academy of Sciences, Beijing, 100049, China 5Henan Tumor Hospital, Zhengzhou, 450008, China 6Department of Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China 7Capital Medical University Clinical Cancer Center, Beijing, 100038, China 8Ninth Clinical Medical College of Peking University, Beijing, 100038, China 9Peking University People's Hospital, Peking University Hepatology Institute, Beijing, 100044, China *These authors have contributed equally to this work **Current Address: Beijing Institute For Drug Control, Beijing, 102206, China Correspondence to: Zhihai Qin, email: zhihai@ibp.ac.cn Keywords: Tumor-associated fibroblasts, retrovirus-insertional mutagenesis, tumor-promoting gene, co-injection model, Ttl Received: July 04, 2017 Accepted: September 21, 2017 Published: October 16, 2017 ABSTRACT Tumor-associated fibroblasts (TAFs) are often essential for solid tumor growth. However, few genetic or epigenetic alterations have been found in TAFs during the progression of solid tumors. Employing a tumor-stromal cell co-injection model, we adapted here retroviral-insertional mutagenesis to stromal cells to identify novel tumor-associated genes in TAFs. We successfully identified 20 gene candidates that might modulate tumor growth if altered in TAFs at genomic level. To validate our finding, the function of one of the candidate genes, tubulin tyrosine ligase (Ttl), was further studied in TAFs from fibrosarcoma, colon, breast and hepatocarcinoma. We demonstrated that down-regulated TTL expression in TAFs indeed promoted tumor growth in mice. Interestingly, decreased expression of TTL in tumor stromal cells also correlated with poor outcome in human colon carcinoma. Thus, the co-injection model of tumor cells with retrovirus-modified fibroblasts proved a valid method to identify tumor-modulating genes in TAFs, allowing for a deeper insight into the role of the stroma for tumor development.
- 16 October 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (57) , 97231-97245
Open AccessIdentifying tumor promoting genomic alterations in tumor-associated fibroblasts via retrovirus-insertional mutagenesis
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Lijie Rong1, 2, 3, *, Yangyang Bian1, *, Shubai Liu2, 3, *, Xiaoman Liu2, 3, Xiao Li2, 3, **, Haiyang Liu2, 3, 4, Jinxue Zhou5, Jirun Peng6, 7, 8, Henghui Zhang9, Hongsong Chen9 and Zhihai Qin1, 2, 3 1Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, China 2Key Laboratory of Protein and Peptide Pharmaceuticals, Chinese Academy of Sciences-University of Tokyo, Beijing, 100101, China 3Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China 4University of Chinese Academy of Sciences, Beijing, 100049, China 5Henan Tumor Hospital, Zhengzhou, 450008, China 6Department of Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China 7Capital Medical University Clinical Cancer Center, Beijing, 100038, China 8Ninth Clinical Medical College of Peking University, Beijing, 100038, China 9Peking University People's Hospital, Peking University Hepatology Institute, Beijing, 100044, China *These authors have contributed equally to this work **Current Address: Beijing Institute For Drug Control, Beijing, 102206, China Correspondence to: Zhihai Qin, email: zhihai@ibp.ac.cn Keywords: Tumor-associated fibroblasts, retrovirus-insertional mutagenesis, tumor-promoting gene, co-injection model, Ttl Received: July 04, 2017 Accepted: September 21, 2017 Published: October 16, 2017 ABSTRACT Tumor-associated fibroblasts (TAFs) are often essential for solid tumor growth. However, few genetic or epigenetic alterations have been found in TAFs during the progression of solid tumors. Employing a tumor-stromal cell co-injection model, we adapted here retroviral-insertional mutagenesis to stromal cells to identify novel tumor-associated genes in TAFs. We successfully identified 20 gene candidates that might modulate tumor growth if altered in TAFs at genomic level. To validate our finding, the function of one of the candidate genes, tubulin tyrosine ligase (Ttl), was further studied in TAFs from fibrosarcoma, colon, breast and hepatocarcinoma. We demonstrated that down-regulated TTL expression in TAFs indeed promoted tumor growth in mice. Interestingly, decreased expression of TTL in tumor stromal cells also correlated with poor outcome in human colon carcinoma. Thus, the co-injection model of tumor cells with retrovirus-modified fibroblasts proved a valid method to identify tumor-modulating genes in TAFs, allowing for a deeper insight into the role of the stroma for tumor development.
- Open Access
- 12 January 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (4) , 1035-1046
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality. Here we show that expression of the tumor suppressor p14ARF (ARF) is upregulated in aggressive subtypes of MIBC. Accumulation of ARF in the nucleolus is associated with poor outcome and attenuated response to chemotherapy. In both genetically engineered mouse models and murine xenograft models of human MIBC, we demonstrate that tumors expressing ARF failed to respond to treatment with the platinum-based chemotherapy agent cisplatin. Resistance was mediated in part by the integrin-binding protein ITGB3BP (CENPR) and reflected ARF-dependent impairment of protein translation, which was exaggerated by drug treatment. Overall, our results highlight a context-dependent role for ARF in modulating the drug response of bladder cancer. Cancer Res; 77(4); 1035–46. ©2017 AACR.
- 12 January 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (4) , 1035-1046
Open AccessARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality. Here we show that expression of the tumor suppressor p14ARF (ARF) is upregulated in aggressive subtypes of MIBC. Accumulation of ARF in the nucleolus is associated with poor outcome and attenuated response to chemotherapy. In both genetically engineered mouse models and murine xenograft models of human MIBC, we demonstrate that tumors expressing ARF failed to respond to treatment with the platinum-based chemotherapy agent cisplatin. Resistance was mediated in part by the integrin-binding protein ITGB3BP (CENPR) and reflected ARF-dependent impairment of protein translation, which was exaggerated by drug treatment. Overall, our results highlight a context-dependent role for ARF in modulating the drug response of bladder cancer. Cancer Res; 77(4); 1035–46. ©2017 AACR.
- Open Access
- 15 October 2012
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 122 (11) , 4094-4104
TNF signaling drives myeloid-derived suppressor cell accumulation
TNF, an inflammatory cytokine that is enriched in the tumor microenvironment, promotes tumor growth and subverts innate immune responses to cancer cells. We previously reported that tumors implanted in TNF receptor–deficient (Tnfr–/–) mice are spontaneously rejected; however, the molecular mechanisms underlying this rejection are unclear. Here we report that TNF signaling drives the peripheral accumulation of myeloid-derived suppressor cells (MDSCs). MDSCs expand extensively during inflammation and tumor progression in mice and humans and can enhance tumor growth by repressing T cell–mediated antitumor responses. Peripheral accumulation of MDSCs was drastically impaired in Tnfr–/– mice. Signaling of TNFR-2, but not TNFR-1, promoted MDSC survival through upregulation of cellular FLICE-inhibitory protein (c-FLIP) and inhibition of caspase-8 activity. Loss of TNFRs impaired the induction of MDSCs from bone marrow cells, but this could be reversed by treatment with caspase inhibitors. These results demonstrate that TNFR-2 signaling promotes MDSC survival and accumulation and helps tumor cells evade the immune system.
- 15 October 2012
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 122 (11) , 4094-4104
Open AccessTNF signaling drives myeloid-derived suppressor cell accumulation
TNF, an inflammatory cytokine that is enriched in the tumor microenvironment, promotes tumor growth and subverts innate immune responses to cancer cells. We previously reported that tumors implanted in TNF receptor–deficient (Tnfr–/–) mice are spontaneously rejected; however, the molecular mechanisms underlying this rejection are unclear. Here we report that TNF signaling drives the peripheral accumulation of myeloid-derived suppressor cells (MDSCs). MDSCs expand extensively during inflammation and tumor progression in mice and humans and can enhance tumor growth by repressing T cell–mediated antitumor responses. Peripheral accumulation of MDSCs was drastically impaired in Tnfr–/– mice. Signaling of TNFR-2, but not TNFR-1, promoted MDSC survival through upregulation of cellular FLICE-inhibitory protein (c-FLIP) and inhibition of caspase-8 activity. Loss of TNFRs impaired the induction of MDSCs from bone marrow cells, but this could be reversed by treatment with caspase inhibitors. These results demonstrate that TNFR-2 signaling promotes MDSC survival and accumulation and helps tumor cells evade the immune system.